Table 2.

Clinical and molecular data on breast cancer patients (test set).

Case	Response	Tumor reduction, %	Histology pre	Age	ER	PR	BCL2	P53	KI67, %	CerbB2	Grading
BC1843	NC	0	invasive ductal; bifocal	63	1	1	200	0	18	1+	2
BC1850	NC	0	invasive lobular	58	1	1	300	0	6	0	2
BC1862	NC	0	invasive lobular a. intraductal	59	1	1	196	0	11	1+	2
BC1871	NC	10	invasive lobular	46	1	1	140	1	24	0	2
BC1869	pCR	100	invasive ductal	60	0	0	0	0	50	0	3
BC1864	pCR	100	invasive a. intraductal (DCIS; 80%)	55	0	0	0	0	50	0	2
BC1421	pCR	100	invasive lobular	71	0	0	0	1	26	0	2
BC1870	cCR	100	invasive ductal	43	0	0	0	1	35	1+ to 2+	2
BC18611	PR	40	invasive ductal a. intraductal (very small)	36	0	0	0	0	35	0	3
BC1879	PR	47	invasive ductal	37	1	1	500	0	45	0	2
BC1866	PR	40	invasive lobular	52	1	1	300	1	24	2+ to 3+	2
BC1837	PR	90	invasive ductal	69	0	0	0	0	48	1+	3
BC1838	PR	80	invasive lobular	59	1	0	50	0	20	1+ to 2+	2
BC1842	PR	92	invasive ductal	68	0	0	0	0	29	1+	2
BC1834	PR	0	invasive ductal a. intraductal (very small)	60	1	1	30	0	10	3+	3
BC1858	PR	0	invasive lobular	62	1	1	140	0	16	1+	2
BC1880	PR	40	invasive ductal and intraductal (5%)	62	1	1	200	0	26	0	2
BC1881	PR	62	invasive ductal	72	0	0	0	1	22	0	2
BC1849	PR	22	invasive ductal	52	1	0	200	0	19	3+	2
BC1839	PR	10	invasive ductal	62	0	0	45	1	16	0	2
BC1513	PR	33	invasive lobular; multicentr.	60	1	1	300	0	10	0	2
BC1877	PR/NC	50	left: invasive lobular a. CLIS Type-A	53	1	1	300	0	6	1+	2
BC1853	PR/NC	0	invasive lobular	51	1	1	400	0	14	0	2
BC1448	PR	68	medullary invasive	50	1	1	30	1	38	3+	3
BC1134	PR/NC	5	invasive lobular	73	1	0	70	0	14	0	2
BC18402	PR	25	invasive ductal	45	1	1	60	0	35	2+ to 3+	3
BC1848	PR	85	invasive ductal; bifocal	42	1	0	500	1	28	3+	2

Note: 1 – This patient has received 4 × EC and, additionally, 4 × Taxol; 2 – this patient has received 3 × EC and, additionally, 3 × FEC.